LXRX – Lexicon Pharmaceuticals Inc.
LXRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
15.27
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
EPS Last/This Y
-0.02
EPS This/Next Y
-0.05
Price
2.45
Target Price
3.86
Analyst Recom
1.8
Performance Q
46.13
Upside
-179.6%
Beta
1.03
Ticker: LXRX
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | LXRX | 2.17 | 0.08 | 3.00 | 38297 |
| 2026-07-14 | LXRX | 2.11 | 0.08 | 0.16 | 38405 |
| 2026-07-15 | LXRX | 2.2 | 0.08 | 0.08 | 38366 |
| 2026-07-16 | LXRX | 2.25 | 0.08 | 0.02 | 38460 |
| 2026-07-17 | LXRX | 2.39 | 0.08 | 0.00 | 38311 |
| 2026-07-20 | LXRX | 2.34 | 0.04 | 0.09 | 28552 |
| 2026-07-21 | LXRX | 2.37 | 0.04 | 0.01 | 28814 |
| 2026-07-22 | LXRX | 2.26 | 0.04 | 0.13 | 29247 |
| 2026-07-23 | LXRX | 2.21 | 0.04 | 0.00 | 29259 |
| 2026-07-24 | LXRX | 2.3 | 0.04 | 0.00 | 29219 |
| 2026-07-27 | LXRX | 2.23 | 0.03 | 0.00 | 31059 |
| 2026-07-28 | LXRX | 2.34 | 0.03 | 0.01 | 31091 |
| 2026-07-29 | LXRX | 2.33 | 0.03 | 0.03 | 31073 |
| 2026-07-30 | LXRX | 2.35 | 0.03 | 0.02 | 31099 |
| 2026-07-31 | LXRX | 2.31 | 0.03 | 0.04 | 31105 |
| 2026-08-03 | LXRX | 2.33 | 0.03 | 0.04 | 31111 |
| 2026-08-04 | LXRX | 2.53 | 0.04 | 0.02 | 31131 |
| 2026-08-05 | LXRX | 2.47 | 0.03 | 1.42 | 31289 |
| 2026-08-06 | LXRX | 2.36 | 0.05 | 0.02 | 31723 |
| 2026-08-07 | LXRX | 2.45 | 0.05 | 0.90 | 31725 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | LXRX | 2.18 | -100.0 | -43.2 | -0.16 |
| 2026-07-14 | LXRX | 2.11 | -100.0 | -42.8 | -0.16 |
| 2026-07-15 | LXRX | 2.21 | -100.0 | -48.2 | -0.16 |
| 2026-07-16 | LXRX | 2.25 | -100.0 | -46.1 | -0.16 |
| 2026-07-17 | LXRX | 2.39 | -100.0 | -49.2 | -0.16 |
| 2026-07-20 | LXRX | 2.34 | -100.0 | -43.2 | -0.16 |
| 2026-07-21 | LXRX | 2.37 | -100.0 | -46.0 | -0.16 |
| 2026-07-22 | LXRX | 2.27 | -100.0 | -41.8 | -0.16 |
| 2026-07-23 | LXRX | 2.31 | -100.0 | -46.3 | -0.16 |
| 2026-07-24 | LXRX | 2.30 | -100.0 | -44.7 | -0.16 |
| 2026-07-27 | LXRX | 2.24 | -100.0 | -43.3 | -0.16 |
| 2026-07-28 | LXRX | 2.33 | -100.0 | -47.8 | -0.16 |
| 2026-07-29 | LXRX | 2.33 | -100.0 | -44.7 | -0.16 |
| 2026-07-30 | LXRX | 2.34 | -100.0 | -45.4 | -0.16 |
| 2026-07-31 | LXRX | 2.30 | -100.0 | -43.6 | -0.16 |
| 2026-08-03 | LXRX | 2.33 | -100.0 | -45.5 | -0.16 |
| 2026-08-04 | LXRX | 2.33 | -100.0 | -45.5 | -0.16 |
| 2026-08-05 | LXRX | 2.47 | -100.0 | -44.1 | -0.16 |
| 2026-08-06 | LXRX | 2.36 | -100.0 | -41.6 | -0.16 |
| 2026-08-07 | LXRX | 2.45 | -100.0 | -47.7 | -0.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | LXRX | 0.90 | 9.60 | 14.36 |
| 2026-07-14 | LXRX | 0.90 | 9.60 | 14.36 |
| 2026-07-15 | LXRX | 0.90 | 9.60 | 14.36 |
| 2026-07-16 | LXRX | 0.90 | 9.60 | 14.36 |
| 2026-07-17 | LXRX | 0.90 | 9.60 | 14.36 |
| 2026-07-20 | LXRX | 0.90 | 8.87 | 14.36 |
| 2026-07-21 | LXRX | 0.90 | 8.87 | 14.36 |
| 2026-07-22 | LXRX | 0.90 | 8.87 | 14.36 |
| 2026-07-23 | LXRX | 0.90 | 8.87 | 14.36 |
| 2026-07-24 | LXRX | 0.90 | 8.87 | 14.36 |
| 2026-07-27 | LXRX | 0.90 | 9.51 | 15.27 |
| 2026-07-28 | LXRX | 0.90 | 9.51 | 15.27 |
| 2026-07-29 | LXRX | 0.90 | 9.51 | 15.27 |
| 2026-07-30 | LXRX | 0.90 | 9.51 | 15.27 |
| 2026-07-31 | LXRX | 0.90 | 9.51 | 15.27 |
| 2026-08-03 | LXRX | 0.90 | 9.48 | 15.27 |
| 2026-08-04 | LXRX | 0.90 | 9.48 | 15.27 |
| 2026-08-05 | LXRX | 0.23 | 9.48 | 15.27 |
| 2026-08-06 | LXRX | 0.23 | 9.48 | 15.27 |
| 2026-08-07 | LXRX | 0.23 | 9.48 | 15.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
0.23
Institutional Transactions
9.48
Beta
1.03
Average Sales Estimate Current Quarter
3
Average Sales Estimate Next Quarter
3
Fair Value
Quality Score
53
Growth Score
35
Sentiment Score
96
Actual DrawDown %
61.2
Max Drawdown 5-Year %
-95.2
Target Price
3.86
P/E
Forward P/E
PEG
P/S
26.3
P/B
5.13
P/Free Cash Flow
EPS
-0.15
Average EPS Est. Cur. Y
-0.16
EPS Next Y. (Est.)
-0.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-147.38
Relative Volume
0.87
Return on Equity vs Sector %
-40.2
Return on Equity vs Industry %
-24.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-47.7
◆
LXRX
Healthcare
$2.45
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
4/25
Volume
7/15
Valuation
9/20
TP/AR
3/10
Options
7/10
RSI
58.4
Range 1M
83%
Sup Dist
15.5%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
4/25
Growth
3/30
Estimates
3/20
Inst/Vol
9/15
Options
5/10
EPS Yr
-17.6%
EPS NY
-24.1%
52W%
84.6%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+57.6% upside
Quality
6/30
Valuation
11/30
Growth
1/25
Stability
6/10
LT Trend
1/5
Upside
+57.6%
Quality
53
Click a card to see score breakdown
Full Analysis →
LXRX — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX
Latest News
—
Caricamento notizie per LXRX…
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading